Gilead posts ZUMA-24 results for axi-cel in LBCL; denikitug trial still active, not recruitingNov 12Weekly roundup, 2 itemsaxicabtagene ciloleuceldenikitugUpdated
Lyell reports Q3 2026 results, new ronde-cel data headed to ASHNov 4Quarterly updateLyell Immunopharma, Inc.
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Kite registers new Phase 3 trial of anitocabtagene autoleucel in newly diagnosed multiple myelomaOct 29Weekly roundup, 4 itemsanitocabtagene autoleucelaxicabtagene ciloleucelUpdated
Lyell reports Q2 2026 results, updated ronde-cel and LYL273 dataAug 6Quarterly updateLyell Immunopharma, Inc.